Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,786.50GBp
13 Dec 2018
Change (% chg)

-32.00 (-1.76%)
Prev Close
1,818.50
Open
1,813.50
Day's High
1,845.00
Day's Low
1,783.00
Volume
489,340
Avg. Vol
588,698
52-wk High
2,089.00
52-wk Low
814.20

Chart for

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.34
Market Cap(Mil.): £2,897.33
Shares Outstanding(Mil.): 240.65
Dividend: 8.50
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 22.78 31.13 34.39
EPS (TTM): 0.53 -- --
ROI: 4.67 15.55 14.96
ROE: 6.88 16.92 16.52

Judge finds Hikma entitled to $31 mln in gout drug dispute

Hikma Pharmaceuticals PLC did not infringe rival Takeda Pharmaceutical Co's patents by selling a gout drug with the same active ingredient as Takeda's Colcrys and is entitled to $31 million in lost profits it suffered due to a prior restraining order, a Delaware federal judge has ruled.

9:09pm EST

Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

LONDON London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients.

Jul 18 2018

Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

LONDON, July 18 London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients.

Jul 18 2018

Earnings vs. Estimates